Last reviewed · How we verify
NCT03526614: RE-SCORE
REpetitive Assessement of SCOREs in Patients on Dual Antiplatelet Therapy
trial in Dual Anti-platelet Therapy in 480 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | University of Roma La Sapienza |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 480 |
| Start date | 1 June 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Italy |
Conditions studied
- Dual Anti-platelet Therapy — all drugs for Dual Anti-platelet Therapy →
Sponsor
University of Roma La Sapienza
Who can join
18 and older, any sex, with Dual Anti-platelet Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients treated with percutaneous coronary intervention (PCI) require dual antiplatelet therapy (DAPT). Preliminary assessment of the PRECISE-DAPT score is mandatory in order to assess the risk of bleeding while on DAPT. The score takes into consideration age, creatinine clearance, haemoglobin, white-blood-cell count and previous spontaneous bleeding. One should consider, however, that some of the variables included in the PRECISE-DAPT score might change with time. As a consequence, the PRECISE-DAPT score should not be considered a static score as it might vary after the initial computation. It remains unknown, however, if the delta PRECISE-SCORE, reflecting the change in score between baseline and follow-up, might predict more reliably the long-term bleeding risk of PCI patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry.
Pelliccia F, Gragnano F, Pasceri V, Marazzi G, et al · · 2022 · cited 3× · PMID 35875853 · DOI 10.1080/09537104.2022.2102602
Verify or expand the search:
- PubMed search for NCT03526614
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Roma La Sapienza trials
Trials by the same sponsor.
- NCT07485023 — Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation · NA · not yet recruiting
- NCT07305519 — The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin · NA · not yet recruiting
- NCT07520968 — ABX Versus CHX in NSPT: a RCT · NA · active not recruiting
- NCT07109596 — Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction · recruiting
- NCT07490574 — Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03526614 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Roma La Sapienza
- Last refreshed: 19 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526614.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing